Risk of HIV Infection in Oral Contraceptive Pill Users: a Meta-analysis
Overview
Authors
Affiliations
Objective: To review the literature and present a summary estimate of the association between HIV-1 acquisition or HIV-1 serostatus and oral contraceptives.
Data Sources: MEDLINE database (January 1986-October 1997), AIDSLINE database (January 1980-October 1997), bibliographies of identified articles, and experts in the field of heterosexual HIV transmission.
Study Selection: In all, 591 articles were examined. Twenty-eight studies provided adequate data to calculate a risk estimate for the association of HIV-1 serostatus or HIV-1 seroconversion with oral contraceptives and were selected for inclusion.
Results: The overall summary odds ratio (OR) for the association between seroprevalent or seroincident HIV-1 infection and use of oral contraceptives in the 28 studies was 1.19 (95% confidence interval [CI], 0.99-1.42). The summary OR for 21 cross-sectional studies was 1.21 (95% CI, 1.01-1.44), whereas the summary relative risk for seven prospective studies was 1.32 (95% CI, 1.12-1.57). Study quality was assessed by applying a scale reflecting study design, measurement of exposure, ability to assess confounding, and publication status. The summary OR for the eight best studies was 1.60 (95% CI, 1.05-2.44). When analysis was limited to studies conducted in Africa, the summary OR was 1.45 (95% CI, 1.15-1.83) for the 14 studies overall, and 1.65 (95% CI, 1.09-2.52) for the seven best studies.
Conclusion: This meta-analysis found a significant association between oral contraceptive use and HIV-1 seroprevalence or seroincidence. For women at risk of HIV-1 infection, oral contraceptive use for prevention of pregnancy should be accompanied by condom use for prevention of HIV-1 infection.
Contraceptive Use and Uptake of HIV-Testing among Sub-Saharan African Women.
Center K, Gunn J, Asaolu I, Gibson S, Ehiri J PLoS One. 2016; 11(4):e0154213.
PMID: 27111915 PMC: 4844155. DOI: 10.1371/journal.pone.0154213.
Ralph L, McCoy S, Shiu K, Padian N Lancet Infect Dis. 2015; 15(2):181-9.
PMID: 25578825 PMC: 4526270. DOI: 10.1016/S1473-3099(14)71052-7.
Interferon-ε protects the female reproductive tract from viral and bacterial infection.
Fung K, Mangan N, Cumming H, Horvat J, Mayall J, Stifter S Science. 2013; 339(6123):1088-92.
PMID: 23449591 PMC: 3617553. DOI: 10.1126/science.1233321.
Stringer E, Giganti M, Carter R, El-Sadr W, Abrams E, Stringer J AIDS. 2010; 23 Suppl 1:S69-77.
PMID: 20081390 PMC: 3865610. DOI: 10.1097/01.aids.0000363779.65827.e0.
Hel Z, Stringer E, Mestecky J Endocr Rev. 2009; 31(1):79-97.
PMID: 19903932 PMC: 2852204. DOI: 10.1210/er.2009-0018.